Summary of COVID-19 atilotrelvir studies

1. Lu et al., Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

1,217 patient GST-HG171 early treatment RCT: 13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001).
RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir.
May 2024, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537024001615, https://c19p.org/lu5